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PCoronary Artery Disease
polipoprotein E Genotype and
irculating Interleukin-10 Levels in Patients
ith Stable and Unstable Coronary Artery Disease
imitrios N. Tziakas, MD, PHD,* Georgios K. Chalikias, MD, PHD,*
hristos O. Antonoglou, MD, PHD,† Stavroula Veletza, PHD,‡ Ioannis K. Tentes, PHD,§
lexandros X. Kortsaris, PHD,§ Dimitrios I. Hatseras, MD, PHD,* Juan Carlos Kaski, MD, DSC, FACC
lexandroupolis, Greece; and London, United Kingdom
OBJECTIVES This study was designed to assess the relation between apolipoprotein E (apoE) genotype and
serum interleukin (IL)-10 levels in patients with acute coronary syndrome (ACS) and chronic
stable angina (CSA).
BACKGROUND Genetic variations in the apoE gene affect the risk for coronary artery disease (i.e., carriers of
the e4 allele have an increased risk). Increased levels of C-reactive protein (CRP), an
inflammatory marker, correlate with an increased risk of acute coronary events, whereas
increased IL-10 concentrations have an atheroprotective role. Studies have reported a
negative association between the apoE e4 allele and CRP levels.
METHODS Apolipoprotein E genotypes were assessed in 166 consecutive ACS patients (119 men, mean
age 68 years, interquartile range [IQR] 60 to 74 years) and 70 CSA patients (54 men, mean
age 65 years, IQR 62 to 68 years). Serum IL-10 and CRP were assessed at study entry.
RESULTS Analysis of covariance showed that genetic variation in the apoE gene locus significantly
influences serum IL-10 levels in both ACS (p  0.009) and CSA patients (p  0.013).
Among ACS patients, IL-10 levels were lower in E3/E4 carriers compared with E3/E3
carriers (p  0.01) and marginally lower compared with E2/E3 carriers (p  0.065). Among
CSA patients, IL-10 levels were lower in E3/E4 carriers compared with E2/E3 carriers (p 
0.004) and marginally lower compared with E3/E3 carriers (p  0.086).
CONCLUSIONS The IL-10 concentrations differ in ACS and in CSA patients with different apoE genotypes.
The e4 allele was associated with a trend toward lower IL-10 serum levels. Our results may
provide an explanation of findings in previous studies that cardiovascular risk is higher in e4
carriers despite the presence of low CRP levels. (J Am Coll Cardiol 2006;48:2471–81)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.032© 2006 by the American College of Cardiology Foundation
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apolipoprotein E (apoE) is a structural component of
oth chylomicrons and very low-density lipoprotein
LDL) remnants. Apolipoprotein E is thought to play a
entral role in atherosclerosis by participating in overall
lasma cholesterol homeostasis, mainly via the regulation
f hepatic uptake of remnant lipoproteins, by facilitating
holesterol efflux from macrophage foam cells within
therosclerotic lesions, and by modifying inflammatory
esponses (1). Apolipoprotein E displays genetic poly-
orphism with three common alleles, e2, e3, and e4, in
single-gene locus in chromosome 19 that give rise to 3
omozygous (apoE2/2, apoE3/3, apoE4/4) and 3 het-
rozygous genotypes (apoE2/3, apoE2/4, apoE3/4) (2).
he apoE allele e4 is associated with increased LDL
holesterol levels and decreased apoE plasma concentra-
From the *University Cardiology Department, Democritus University of Thrace,
lexandroupolis, Greece; †2nd Department of Internal Medicine, Democritus
niversity of Thrace, Alexandroupolis, Greece; ‡Department of Medical Biology,
emocritus University of Thrace, Alexandroupolis, Greece; §Department of Bio-
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ascular Biology Research Centre, Division of Cardiac and Vascular Sciences,
t. George’s, University of London, London, United Kingdom.I
Manuscript received June 7, 2006; revised manuscript received July 31, 2006,
ccepted August 7, 2006.ions (2,3). Conversely, the e2 allele is associated with
educed LDL cholesterol levels and higher apoE plasma
oncentrations (2,3). There is evidence that the e4 allele
s associated with increased risk of coronary artery disease
CAD), whereas the e2 allele is considered to confer
rotection against CAD. The mechanisms responsible
or these associations have not been elucidated (4 – 6).
Inflammation plays a central role in the pathogenesis of
therosclerosis (7). Increased levels of the acute-phase reac-
ant C-reactive protein (CRP) predict future cardiovascular
vents (8–10), whereas elevated serum levels of interleukin
IL)-10, an anti-inflammatory cytokine with atheroprotec-
ive actions (11), are known to be associated with a more
avorable prognosis (12). Recent studies investigating the
ssociation between apoE and inflammatory responses
howed that genetic variation in apoE gene locus influences
RP levels (13–15). Indeed, carriers of the e4 allele were
ound to have reduced CRP levels compared with carriers of
3 or e2 alleles (13–15).
These findings contrast with the fact that the e4 allele is
ost strongly associated with CAD; therefore, we sought to
ssess the impact of the apoE genotypic variation on serum
L-10 levels.
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atients. We assessed 166 consecutive white patients who
ere admitted to the coronary care unit with a diagnosis of
cute coronary syndrome (ACS), including acute myocar-
ial infarction (MI) (both ST-segment elevation [STEMI]
nd non–ST-segment elevation [NSTEMI]) and unstable
ngina (UA). In addition, we studied 70 white chronic
table angina (CSA) patients undergoing coronary arteriog-
aphy for the assessment of angina chest pain.
Myocardial infarction and UA were diagnosed using the
oint European Society of Cardiology/American College of
ardiology criteria (16–18) as follows: MI was diagnosed in
he presence of prolonged (20 min) chest discomfort in
he past 24 h, with ST-segment changes suggestive of
yocardial ischemia or necrosis on the standard 12-lead
lectrocardiogram, associated with increased serum markers
f myocardial damage measured on at least 2 occasions
uring the first 24 h after the index event (2-fold increase
ver the upper normal range required for troponin T 0.1
g/ml). Myocardial infarction patients were considered to
ave STEMI in the presence of 0.2 mV ST-segment
levation at the J point in 2 or more contiguous electrocar-
iogram leads. The NSTEMI was diagnosed in the pres-
nce of new ST-segment depression (0.1 mV) or T-wave
nversion (0.3 mV) in 2 or more contiguous leads (16–18).
nstable angina was defined as anginal pain at rest fulfilling
raunwald’s IIIb criteria with transient significant ischemic
T-segment or T-wave changes, or both, without evidence
f myocardial damage (18). Stable CAD was defined as
ypical exertional chest pain relieved by rest and/or nitrates,
ithout a change in frequency or pattern for 3 months
efore study entry, and with a positive response (1 mm
T-segment depression) to exercise stress testing or revers-
ble perfusion defects during myocardial perfusion scintig-
aphy. All CSA patients had50% coronary artery stenoses
n coronary angiography.
Whole blood and serum samples were obtained from
very patient at study entry for the assessment of apoE
enotype and inflammatory markers, respectively. The use
Abbreviations and Acronyms
ANCOVA  analysis of covariance
apoE  apolipoprotein E
CAD  coronary artery disease
CRP  C-reactive protein
CSA  chronic stable angina
HDL  high-density lipoprotein
IL  interleukin
IQR  interquartile range
LDL  low-density lipoprotein
MI  myocardial infarction
NSTEMI  non–ST-segment elevation myocardial
infarction
STEMI  ST-segment elevation myocardial infarction
UA  unstable anginaf concomitant medication at study entry was recorded. mThe study was approved by the hospital’s ethics commit-
ee, and all patients gave written informed consent before
tudy entry. We did not include patients with a history of
xcessive alcohol intake (8 U/week) or hematologic, neo-
lastic, renal, liver, or thyroid disease. Furthermore, patients
ho had infectious or autoimmune diseases, familial hyper-
ipidemia, or triglycerides 400 mg/dl or who were under-
oing surgical procedures in the preceding 3 months were
lso excluded. None of the patients included in the study
as receiving treatment with anti-inflammatory drugs or
ormone replacement therapy.
aboratory methods. In all patients, 2 peripheral blood
amples were drawn within 1 h from admission. Whole-
lood specimens for apoE genotype measurement were
ollected in standard vacutainer tubes containing ethyl-
nediaminetetraacetic acid as anticoagulant and immedi-
tely frozen and stored at 20°C. Blood samples intended
or biochemical measurements were centrifuged at 3,000
pm for 10 min, and the serum thus obtained was frozen and
tored at 70°C until assessment.
Genomic deoxyribonucleic acid was extracted from whole
lood samples by salting out as described by Miller et al.
19). We used semi-nested polymerase chain reaction fol-
owing a modification of the procedure described by Hixson
t al. (20) to amplify a 218-bp-long deoxyribonucleic acid
ragment containing 2 polymorphic sites at positions 112
Arg¡Cys) and 158 (Arg¡Cys). The following primers
ere used for amplification: 1EF2: 5= ACA GAA TTC
CC CCG GCC TGG TAC ACT GCC A 3=, 2AER: 5=
AA GCT TGG CAC GGC TGT CCA A 3=, and 2ERC:
= TCC AAG GAG CTG CAG GCG GCG CA 3=. Alleles
ere defined as follows: e2 by T and Arg at position 112, by
at position 158, and no HhaI recognition site at either;
llele e3 by T at position 112, C and HhaI recognition site
t position 158; and allele e4 by C at position 112, C at
osition 158, and HhaI recognition sites at both positions.
he polymerase chain reaction product was subsequently
igested with HhaI and the produced fragments were
ssessed in a 4% metafor agarose gel.
Sandwich enzyme immunoassay was performed for mea-
uring concentrations of serum IL-10 using Quantikine HS
uman IL-10 (R&D Systems Inc., Minneapolis, Minne-
ota) (21) commercial kits with monoclonal antibodies, with
minimum detectable concentration 0.5 pg/ml. The
ntra-assay precision and inter-assay precision of the
ethod were 8.5% and 15.6%, respectively.
Troponin T measurement was performed using commer-
ially available assays (Cardiac Troponin T, Roche Diag-
ostics, Basel, Switzerland) with a minimum detectable
oncentration of 0.01 ng/ml on the Elecsys 1010 (Roche
iagnostics) based on electrochemiluminescence method.
he intra-assay precision and inter-assay precision of the
ethod were 1.4% and 5.1%, respectively.
High-sensitivity CRP was measured by immunoneph-
lometry using Dade Behring (Marburg, Germany) com-
ercial kits (22), with a minimum detectable concentration
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December 19, 2006:2471–81 ApoE Gene Locus and Serum IL-10 in CADf 0.17 mg/l. Total, LDL, and high-density lipoprotein
HDL) cholesterol measurements, as well as triglycerides
nd creatinine measurements, were carried out by our
iochemistry department using standard methods.
tatistical analysis. Values are expressed as median values
ith interquartile ranges (IQRs). The Kolmogorov-Smirnof
est was used to examine the distribution of the variables
nder assessment. Differences in continuous variables be-
ween 2 groups were assessed using Mann-Whitney U test,
hereas differences between 2 groups were assessed using
ruskal-Wallis test. Comparisons between categorical vari-
bles were performed by chi-square test or Fisher exact test
hen required. Although the E3/E3, E3/E4 and E2/E3
enotypes were present in both the ACS and CSA patient
roups, the other apoE genotypes (E2/E4 and E2/E2) were
arely found in these patients; therefore, comparisons for
hose specific genotypes were not performed.
Before carrying out parametric statistical procedures, all
ariables that were not normally distributed were transformed
o ensure a more normal distribution and equal variance before
urther parametric analysis and to fulfill statistical requirements
or multiple regression analysis and analysis of covariance.
pecifically, total, HDL, and LDL cholesterol as well as
riglyceride levels were logarithmically transformed, and IL-10
nd CRP levels were square-root transformed.
Significant covariates for IL-10 and CRP were identified
sing stepwise linear regression models where age, gender,
ody mass index, disease on admission (presence of STEMI vs.
STEMI/UA), smoking status, presence of diabetes mellitus,
ypertension, dyslipidemia, family history of CAD, previous
istory of CAD, lipid levels, and medication use were entered
nto the analyses. Significance levels of 0.05 and 0.1 were
hosen to exclude and include terms, respectively. After iden-
ification of significant covariates, we tested differences in
L-10 and CRP levels among apoE genotypes using analysis of
ovariance (ANCOVA) adjusting for appropriate covariates.
ubsequent post-hoc least significant difference tests were used
o evaluate differences in IL-10 and CRP levels among the 3
roups in a pairwise fashion.
All analyses were performed separately for ACS and CSA
atients.
Correlation analysis between variables of the study was
arried out using Spearman’s correlation coefficient r. All
tatistical calculations were performed using SPSS 12.0
tatistical software package (SPSS Inc., Chicago, Illinois). A
value 0.05 was considered statistically significant.
ESULTS
tudy population—baseline characteristics. Apolipopro-
ein E genotype was measured in 166 ACS patients (119
72%] men, median age 68 [IQR 60 to 74] years) and 70
SA patients (54 [77%] men, median age 65 [IQR 62 to
8] years). Of the 236 study participants, 164 (69.5%) were
3/E3 carriers, 52 (22%) E3/E4 carriers, and 18 (7.6%)
2/E3 carriers. One patient (0.4%) had the E2/E4 geno- (ype, 1 patient (0.4%) had the E2/E2 genotype, and no
atients had the E4/E4 genotype. There were no significant
ifferences in the distribution of apoE genotype and allele
requency between ACS and CSA patient groups (Table 1).
Baseline characteristics of patients with CSA and ACS
re presented in Table 2. A higher proportion of ACS
atients had a history of previous CAD. Established risk
actors for CAD were similar in the 2 groups, with the
xception of family history of CAD, which was more common
n stable CAD patients than in ACS patients. The medica-
ions taken by both groups at study entry were similar, with
he exception of beta-blockers, calcium channel blockers,
nd aspirin, which, as expected, were significantly more
ommon in the stable CAD group. Total cholesterol, LDL
holesterol, and CRP levels were significantly higher in
CS patients. In contrast, HDL cholesterol and IL-10
evels were higher in the stable CAD group.
poE polymorphism in the ACS study population. Of
he 166 ACS study participants, 116 (70%) were E3/E3
arriers, 34 (20.4%) were E3/E4 carriers, and 14 (8.4%)
ere E2/E3 carriers. One patient (0.6%) had the E2/E4
enotype, 1 patient (0.6%) had the E2/E2 genotype, and
one of the patients had the E4/E4 genotype.
The LDL cholesterol levels were similar among the 3
poE genotype groups; however, LDL cholesterol levels
ere non-significantly higher among the E3/E4 carriers.
able 3 summarizes baseline characteristics and biochem-
stry results among the 3 different apoE genotype groups at
tudy entry.
ssociation of the apoE polymorphism and IL-10 levels
n ACS patients. Nonparametric analysis of variance
howed that genetic variance in apoE gene locus signifi-
antly influences serum IL-10 levels among ACS patients
p  0.008) (Fig. 1). As multiple a priori pairwise compar-
sons of IL-10 levels in different apoE genotype subgroups
able 1. Distribution of the ApoE Polymorphism in Acute
oronary Syndrome Patients (n  166) and Chronic Stable
ngina Patients (n  70)
ApoE Genotype ACS, n (%) CSA, n (%)
2 1 (0.6%) —
3 14 (8.4%) 4 (5.7%)
4 1 (0.6%) —
3 116 (70%) 48 (68.6%)
4 34 (20.4%) 18 (25.7%)
4 — —
otal 166 70
hi-square  1.94,
p  0.746
Allele Frequency* p Value
2 0.0512 0.0285 0.401
3 0.8433 0.8428 0.988
4 0.1054 0.1285 0.987
Allele frequency was calculated by allele counting, p for chi-square contingency test.
ACS  acute coronary syndrome; ApoE  apolipoprotein E; CSA  chronic
table angina; e  e allele.Table 3) may be subject to type I error risk, parametric
a
p
t
a

f
v
0
L
t
p
c
c
p
b
c
r
s
w
t
(
(
I
(
A
i
l
p
e
ction;
e angin
2474 Tziakas et al. JACC Vol. 48, No. 12, 2006
ApoE Gene Locus and Serum IL-10 in CAD December 19, 2006:2471–81nalysis of covariance with subsequent post-hoc tests were
erformed.
Using stepwise linear regression analysis, HDL choles-
erol (for log HDL cholesterol beta  0.168, p  0.029)
nd LDL cholesterol levels (for log LDL cholesterol beta
0.194, p  0.015) were identified as significant covariates
or IL-10 levels. The independent contribution of the genetic
ariation in apoE locus on IL-10 levels was preserved (p 
.009) in an ANCOVA model after adjustment for HDL and
DL cholesterol levels (Table 4). Post-hoc analysis showed
hat E3/E4 carriers had significantly lower IL-10 levels com-
ared with E3/E3 carriers (p  0.01). Furthermore, E3/E4
arriers had lower, yet marginally not significant, IL-10 levels
ompared with E2/E3 carriers (p  0.065). In contrast,
ost-hoc tests did not show any difference in IL-10 levels
Table 2. Baseline Characteristics of 166 Patien
70 Patients With Chronic Stable Angina (CSA
ACS (n 
Age (yrs) 68 (60–7
Men, n (%) 119 (72%)
BMI (kg/m2) 29 (28–3
Disease, n (%)
STEMI 69 (42%)
NSTEMI 47 (28%)
UA 50 (30%)
Stable angina —
Risk factors, n (%)
Smoking 52 (31%)
Diabetes mellitus 56 (34%)
Hypertension 110 (66%)
Dyslipideamia 107 (65%)
Family history 20 (12%)
Prior CAD 69 (42%)
Previous MI 46 (28%)
Prior CVD disease 16 (10%)
Prior PCI 18 (11%)
Prior CABG 14 (8%)
Medications, n (%)
ACE inhibitor 53 (32%)
Beta-blocker 49 (29%)
Calcium channel blocker 55 (33%)
Nitrate 50 (30%)
ARB 14 (8%)
Statin 53 (32%)
Aspirin 60 (36%)
Clopidogrel 22 (13%)
Biochemistry
Creatinine (mg/dl) 1 (1–1.2
Total cholesterol (mg/dl) 214 (189–
LDL cholesterol (mg/dl) 126 (115–
HDL cholesterol (mg/dl) 46 (43–5
Triglycerides (mg/dl) 128 (108–
CRP (mg/l) 9 (5.5–1
IL-10 (pg/ml) 6.7 (5.1–7
*p for chi-square test. †p for Mann-Whitney U nonparamet
ACE  angiotensin-converting enzyme; ARB  angioten
artery bypass grafting; CAD  coronary artery disease; CVD
high-density lipoprotein; IL  interleukin; LDL  low-dens
NSTEMI  non–ST-segment elevation myocardial infar
ST-Segment elevation myocardial infarction; UA  unstabletween E3/E3 and E2/E3 carriers (p  0.775). iAs the presence of myocardial necrosis may influence
ytokine levels, as well as inflammatory and counter-
egulatory mechanisms, we assessed the effect of e4 allele on
erum IL-10 levels in a subgroup of unstable angina patients
ithout evidence of myocardial damage as assessed by
roponin T measurements. Troponin T-negative patients
n  50) who were carriers of the e4 allele had significantly
p  0.006) lower IL-10 levels (n  9, IL-10: 4.5 pg/ml,
QR 4.1 to 5.6) compared with noncarriers of the e4 allele
n  41, IL-10: 6.7 pg/ml, IQR 5.4 to 7.7).
ssociation of the apoE polymorphism and CRP levels
n ACS patients. Kruskal-Wallis test showed that CRP
evels differed significantly in the different apoE gene
olymorphism groups (p  0.001). To minimize type I
rror risk associated with multiple a priori pairwise compar-
ith Acute Coronary Syndrome (ACS) and
CSA (n  70) p Value
65 (62–68) 0.167
54 (77%) 0.424
29 (27–30) 0.750
— n/a
— n/a
— n/a
70 (100%) n/a
24 (34%) 0.651
22 (31%) 0.764
46 (66%) 1
36 (51%) 0.08
18 (26%) 0.012*
12 (17%) 0.001*
7 (10%) 0.001*
6 (9%) 1
2 (3%) 0.078
4 (6%) 0.597
26 (37%) 0.453
34 (49%) 0.007*
34 (49%) 0.028*
24 (34%) 0.542
12 (17%) 0.068
30 (43%) 0.135
44 (63%) 0.001*
16 (23%) 0.081
1 (1–1.2) 0.848
198 (160–223) 0.011†
112 (83–137) 0.001†
52 (46–60) 0.001†
147 (98–193) 0.560
4 (2–12) 0.001†
16.2 (12.8–21.3) 0.001†
t.
eptor blocker; BMI  body mass index; CABG  coronary
rebrovascular disease; CRP  C-reactive protein; HDL 
oprotein; MI  myocardial infarction; n/a  not applicable;
PCI  percutaneous coronary intervention; STEMI 
a.ts W
)
166)
4)
0)
)
230)
146)
1)
171)
0)
.5)
ric tes
sin rec
 ce
ity lipsons (Table 3), parametric analyses of covariance with
Table 3. Baseline Characteristics Among the Most Common ApoE Genotypes in the Acute Coronary Syndrome Study Population (n  164)
ApoE Gene Polymorphism
Overall
p Value
E3/E3 vs. E2/E3
p Value
E3/E3 vs. E3/E4
p Value
E2/E3 vs. E3/E4
p ValueE3/E3 E2/E3 E3/E4
Patients, n (%) 116 (70%) 14 (8.4%) 34 (20.4%) n/a n/a n/a n/a
Age (yrs) 68 (61–74) 67 (59–76) 67 (58–71) 0.789 0.786 0.375 0.828
Men, n (%) 86 (74%) 9 (64%) 24 (71%) 0.707 0.524 0.666 0.738
BMI (kg/m2) 29 (28–30) 28.5 (28–30) 29 (28–30) 0.612 0.334 0.906 0.383
Disease, n (%) 0.632 0.333 0.731 0.656
STEMI 45 (41%) 7 (50%) 15 (44%)
NSTEMI 30 (26%) 5 (36%) 10 (30%)
UA 39 (34%) 2 (14%) 9 (27%)
Risk factors, n (%)
Smoking 37 (32%) 3 (21%) 11 (32%) 0.715 0.548 1 0.510
Diabetes mellitus 39 (34%) 3 (21%) 13 (38%) 0.533 0.547 0.683 0.328
Hypertension 78 (67%) 10 (71%) 20 (59%) 0.594 1 0.414 0.521
Dyslipidemia 80 (69%) 8 (57%) 19 (56%) 0.297 0.379 0.216 1
Family history 12 (10%) 3 (21%) 5 (15%) 0.430 0.206 0.539 0.676
Prior CAD disease 51 (44%) 3 (21%) 15 (44%) 0.262 0.152 1 0.196
Previous MI 34 (29%) 2 (14%) 10 (29%) 0.488 0.347 1 0.465
Prior CVD disease 10 (9%) 0 (0%) 5 (15%) 0.258 0.599 0.332 0.303
Prior PCI 15 (13%) 1 (7%) 2 (6%) 0.457 1 0.362 1
Prior CABG 9 (8%) 2 (14%) 3 (9%) 0.710 0.337 0.735 0.621
Medications, n (%)
ACE inhibitor 34 (29%) 6 (43%) 12 (35%) 0.519 0.360 0.530 0.746
Beta-blocker 39 (34%) 3 (21%) 7 (21%) 0.265 0.547 0.204 1
Calcium channel blocker 44 (38%) 2 (14%) 8 (23%) 0.087 0.136 0.153 0.701
Nitrate 38 (33%) 2 (14%) 9 (27%) 0.321 0.224 0.535 0.469
ARB 12 (10%) 1 (7%) 1 (3%) 0.390 1 0.299 0.503
Statin 37 (32%) 4 (29%) 12 (35%) 0.888 1 0.836 0.746
Aspirin 43 (37%) 4 (29%) 12 (35%) 0.819 0.769 1 0.746
Clopidogrel 19 (16%) 1 (7%) 2 (6%) 0.222 0.694 0.163 1
Biochemistry
Creatinine (mg/dl) 1.1 (1–1.2) 1.1 (1–1.1) 1.1 (1–1.2) 0.667 0.607 0.420 0.917
Total cholesterol (mg/dl) 214 (194–227) 198 (171–227) 212 (182–246) 0.459 0.232 0.677 0.334
LDL cholesterol (mg/dl) 126 (117–139) 135 (109–149) 144 (112–155) 0.190 0.476 0.081 0.426
HDL cholesterol (mg/dl) 46 (43–50) 43 (42–50) 44 (41–51) 0.272 0.268 0.185 0.658
Triglycerides (mg/dl) 128 (111–167) 129 (80–204) 138 (104–185) 0.651 0.499 0.543 0.454
CRP (mg/l) 9 (8–10) 9 (8–10) 4 (3–5) 0.001* 0.913 0.001† 0.001†
IL-10 (pg/ml) 6.7 (5.4–7.7) 7 (5.2–7.8) 5.6 (4.2–6.7) 0.008* 0.620 0.003† 0.049†
One patient (0.6%) had E2/E2 apoE gene polymorphism and 1 patient (0.6%) had E2/E4 apoE gene polymorphism, whereas none of the patients had the E4/E4 apoE gene polymorphism. *p for Kruskal-Wallis nonparametric test.
†p for Mann-Whitney U nonparametric test.
Abbreviations as in Table 2.
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ApoE Gene Locus and Serum IL-10 in CAD December 19, 2006:2471–81ubsequent post-hoc tests were used to compare CRP levels
etween different apoE genotype subgroups.
Stepwise linear regression analysis identified the presence
f STEMI versus NSTEMI/UA (beta 0.168, p 0.014),
DL-cholesterol levels (for log HDL cholesterol beta 
0.171, p  0.014), triglyceride levels (for log triglyceride
eta  0.239, p  0.001), and smoking status (beta 
.143, p  0.039) as significant covariates for CRP levels.
-reactive protein levels remained significantly different
p  0.001) among the different apoE gene polymorphism
roups in an ANCOVA model after adjustment for all the
forementioned covariates (Table 4). Post-hoc analysis
howed that E3/E4 carriers had significantly lower CRP
evels compared with E3/E3 carriers (p 0.001) and E2/E3
arriers (p  0.001). In contrast, post-hoc tests did not
how any difference in CRP levels between E3/E3 and
2/E3 carriers (p  0.729).
orrelation analysis in ACS patients. We did not observe
significant association between serum IL-10 levels and
RP levels in the ACS study group (n  164, r  0.138,
 0.078). Furthermore, no association was found between
igure 1. Interleukin-10 levels among apolipoprotein (apo)E genotype
roups in acute coronary syndrome patients group. Box plots represent
edian levels with 25th and 75th percentiles of observed data; whiskers
epresent the 5th and 95th percentiles in each group.
Table 4. Estimated Adjusted Means of Interle
Different ApoE Genotypes in the Acute Coron
ApoE Genotype
IL-10 (pg/ml)
Estimated Mean*
E3/E3 6.7
E2/E3 6.9
E3/E4 5.6
ANCOVA for IL-10 model: R2 0.293. ApoE genotype (F
cholesterol (F  5.44, p  0.021) and log HDL cholesterol (
before entering the model, we present the squared estimated
(F 23.48, p 0.001). Evaluated at covariates in the model l
(STEMI vs. NSTEMI) (F 5.78, p 0.017), log triglycerid
†Because CRP was square root transformed before enteringApoE  apolipoprotein E; CI  confidence interval; F 
abbreviations as in Table 2.he aforementioned variables among E3/E3 carriers (n 
16, r  0.068, p  0.467), E2/E3 carriers (n  14, r 
0.256, p 0.377), and E3/E4 carriers (n 34, r 0.030,
 0.865).
poE polymorphism in the CSA study population. Of
he 70 CSA study participants, 48 (68.6%) were E3/E3
arriers, 18 (25.7%) were E3/E4 carriers, and 4 (5.7%) were
2/E3 carriers; none of the patients had the E4/E4, E2/E2,
r E2/E4 genotype. Total cholesterol (p  0.049), LDL
holesterol (p  0.003), and HDL cholesterol (p  0.007)
evels were significantly different among the 3 apoE geno-
ype groups. In particular, E3/E4 carriers had significantly
igher total (p  0.031) and LDL cholesterol (p  0.003)
evels compared with E3/E3 carriers. In addition, E2/E3
arriers had higher HDL-cholesterol levels compared to
3/E3 (p  0.001) and E3/E4 carriers (p  0.042).
able 5 summarizes baseline characteristics and bio-
hemistry results among the 3 different apoE genotype
roups at study entry.
ssociation regarding the apoE polymorphism and IL-10
evels in CSA patients. Nonparametric analysis of variance
howed that genetic variance in the apoE gene locus
ignificantly influences serum IL-10 levels (p  0.001)
mong CSA patients (Fig. 2). As multiple a priori pairwise
omparisons regarding IL-10 levels between different apoE
enotype subgroups (Table 5) are subject to type I error risk,
arametric analysis of covariance with subsequent post-hoc
ests were performed.
Using stepwise linear regression analysis, HDL choles-
erol (for log HDL cholesterol beta  0.528, p  0.001),
DL cholesterol (for log LDL cholesterol beta  0.263,
 0.022), triglyceride levels (for log triglycerides beta 
.456, p  0.001), and calcium channel blocker use (beta 
.292, p  0.011) were identified as significant covariates
or IL-10 levels. The independent contribution of the
enetic variation in apoE locus on IL-10 levels was pre-
erved (p 0.013) in an ANCOVA model after adjustment
or calcium channel blocker use, HDL and LDL choles-
erol, and triglyceride levels (Table 6). Post-hoc analysis
howed that E3/E4 carriers had significantly lower IL-10
evels compared with E2/E3 carriers (p  0.004). Further-
10 (IL-10) and C-Reactive Protein (CRP) in
Syndrome Patient Group
CRP (mg/l)
CI Estimated Mean† 95% CI
–7.1 9.1 8.3–9.8
–8.1 8.7 6.7–10.9
–6.3 4.5 3.6–5.5
6, p 0.009). Evaluated at covariates in the model log LDL
93, p  0.049). *Because IL-10 was square root transformed
s. ANCOVA for CRP model: R2  0.306. ApoE genotype
L cholesterol (F 5.53, p 0.020), disease on presentation
13.53, p 0.001), and smoking status (F 3.9, p 0.05).
odel, we present the squared estimated means.ukin-
ary
95%
6.3
5.7
4.9
 13.2
F  3.
mean
og HD
es (F
the mf statistic for each variable included in the model; other
Table 5. Baseline Characteristics Among the Most Common ApoE Genotypes in the Chronic Stable Angina Study Population (n  70)
ApoE Gene Polymorphism
Overall
p Value
E3/E3 vs. E2/E3
p Value
E3/E3 vs. E3/E4
p Value
E2/E3 vs. E3/E4
p ValueE3/E3 E2/E3 E3/E4
Patients, n (%) 48 (68.6%) 4 (5.7%) 18 (25.7%) n/a n/a n/a n/a
Age (yrs) 63 (61–69) 65 (64–66) 65 (64–67) 0.857 0.830 0.618 0.652
Men, n (%) 36 (75%) 4 (100%) 14 (78%) 0.518 0.562 1 0.554
BMI (kg/m2) 29 (28–31) 30 (28–31) 28 (27–30) 0.156 0.435 0.117 0.098
Risk factors, n (%)
Smoking 20 (42%) — 4 (22%) 0.110 0.151 0.165 0.554
Diabetes mellitus 18 (37%) 2 (50%) 2 (11%) 0.086 0.634 0.069 0.135
Hypertension 28 (58%) 4 (100%) 17 (78%) 0.110 0.151 0.165 0.554
Dyslipidemia 24 (50%) 4 (100%) 8 (44%) 0.115 0.785 0.096
Family history 12 (25%) — 6 (33%) 0.378 0.562 0.543 0.541
Prior CAD disease 6 (12%) — 6 (33%) 0.087 1 0.073 0.541
Previous MI 4 (8%) — 2 (11%) 0.769 1 0.661 1
Prior CVD disease 4 (8%) — 2 (11%) 0.769 1 0.661 1
Prior PCI 2 (4%) — — 0.624 1 1 n/a
Prior CABG 2 (4%) — 2 (11%) 0.489 1 0.298 1
Medications, n (%)
ACE inhibitor 18 (37%) 2 (50%) 6 (33%) 0.820 0.634 1 0.602
Beta-blocker 26 (54%) 2 (50%) 6 (33%) 0.320 1 0.171 0.602
Calcium channel blocker 22 (46%) 2 (50%) 10 (56%) 0.779 1 0.584 1
Nitrate 18 (37%) — 6 (33%) 0.314 0.285 1 0.541
ARB 10 (21%) — 2 (11%) 0.417 0.576 0.487 1
Statin 24 (50%) 2 (50%) 4 (22%) 0.122 1 0.153 0.292
Aspirin 28 (58%) 4 (100%) 12 (67%) 0.235 0.151 0.585 0.541
Clopidogrel 12 (25%) 2 (50%) 2 (11%) 0.201 0.291 0.318 0.135
Biochemistry
Creatinine (mg/dl) 1 (1–1.2) 1.1 (1.1–1.3) 1.1 (1–1.3) 0.114 0.206 0.076 0.652
Total cholesterol (mg/dl) 190 (154–219) 178 (175–182) 217 (186–253) 0.049* 0.359 0.031† 0.098
LDL cholesterol (mg/dl) 111 (81–131) 84 (79–90) 136 (112–163) 0.003* 0.139 0.003† 0.014†
HDL cholesterol (mg/dl) 51 (44–59) 68 (66–71) 48 (48–56) 0.007* 0.001† 0.488 0.042†
Triglycerides (mg/dl) 151 (116–215) 126 (94–158) 147 (76–164) 0.269 0.359 0.150 0.774
CRP (mg/l) 5 (2–16) 10 (4–17) 1 (1–3) 0.001* 0.607 0.001† 0.001†
IL-10 (pg/ml) 16.2 (13–21.9) 35.6 (20.1–51.1) 14.2 (8–18.8) 0.001* 0.055 0.039† 0.014†
None of the patients had E2/E2, E2/E4, or E4/E4 apoE gene polymorphism. *p for Kruskal-Wallis nonparametric test. †p for Mann-Whitney U nonparametric test.
Abbreviations as in Table 2.
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cant, IL-10 levels compared with E3/E3 carriers (p 
.086). Post-hoc tests also showed that E2/E3 carriers had
ignificantly higher IL-10 levels compared with E3/E3
arriers (p  0.02).
ssociations between the apoE polymorphism and CRP
evels in CSA patients. Kruskal-Wallis test showed that
RP levels differed significantly in the different apoE gene
olymorphism groups (p 0.001). Similarly, because of the
ype I error risk associated with multiple a priori pairwise
omparisons (Table 5), parametric ANCOVA with subse-
uent post-hoc tests were used to compare CRP levels
etween different apoE genotype subgroups.
Stepwise linear regression analysis identified HDL cho-
esterol levels (for log HDL cholesterol beta0.253, p
.025), and beta-blocker use (beta0.349, p 0.002) as
ignificant covariates for CRP levels. C-reactive protein
evels remained to be significantly different (p  0.001)
mong the different apoE gene polymorphism groups in an
NCOVA model after adjustment for all the aforemen-
ioned covariates (Table 6). Post-hoc analysis showed that
3/E4 carriers had significantly lower CRP levels compared
igure 2. Interleukin-10 levels among apolipoprotein (apo)E genotype
roups in chronic stable angina patients group. Box plots represent median
evels with 25th and 75th percentiles of observed data; whiskers represent
he 5th and 95th percentiles in each group.
Table 6. Estimated Adjusted Means of Interle
Different ApoE Genotypes in Chronic Stable A
ApoE Genotype
IL-10 (pg/ml)
Estimated Mean*
E3/E3 17.8
E2/E3 28.6
E3/E4 14.3
ANCOVA for IL-10 model: R2 0.354. ApoE genotype (F
cholesterol (F  5.95, p  0.018), log LDL cholesterol (F 
and calcium channel blocker use (F  6.47, p  0.013). *Bec
we present the squared estimated means. ANCOVA for CR
Evaluated at covariates in the model log HDL cholesterol leve
†Because CRP was square root transformed before enteringApoE  apolipoprotein E; CI  confidence interval; F 
abbreviations as in Table 2.ith E3/E3 carriers (p  0.001). Furthermore, E3/E4
arriers had lower, yet marginally not significant CRP levels
ompared with E2/E3 carriers (p  0.069). In contrast,
ost-hoc tests did not show any difference in CRP levels
etween E3/E3 and E2/E3 carriers (p  0.809).
orrelation analysis in CSA patients. We did not observe
ny significant association between serum IL-10 levels and
RP levels in CSA study population (n  70, r  0.209,
 0.083). Furthermore, no association was found between
he aforementioned variables among E3/E3 carriers (n 
8, r  0.053, p  0.718), and E3/E4 carriers (n  18,
0.045, p  0.823).
ISCUSSION
ur study is among the first to evaluate the association
etween apoE genotypes and anti-inflammatory markers.
verall, we found that genetic variation in apoE gene locus
ignificantly influences serum IL-10 levels both in ACS and
SA patients and, specifically, that e4 allele carriers are
ssociated with a trend toward lower circulating IL-10
evels. In particular, among ACS patients, IL-10 levels were
ower in E3/E4 carriers compared with E3/E3 and margin-
lly lower compared with E2/E3 carriers. Similarly, among
SA patients IL-10 levels were lower in E3/E4 carriers
ompared to E2/E3 carriers and marginally lower compared
o E3/E3 carriers. In addition, this association was inde-
endent of LDL cholesterol levels, which are known to
iffer in different apoE genotypes and could influence IL-10
erum concentration. This finding is of clinical relevance as
t may provide an explanation to findings in previous reports
hat cardiovascular risk is higher in e4 carriers even in the
resence of low CRP levels, probably as a result of reduced
rotection against the damaging effect of inflammatory
echanisms (4,23).
It is established that a major physiologic role for apoE
s that of receptor-binding ligand, mediating the binding
nd hepatic uptake of chylomicron remnants and apoE-
ontaining lipoproteins by both the LDL receptor and LDL
eceptor-related protein (24). The apoE polymorphisms,
hich presumably arose as mutations of the e3 allele, are the
esult of variation in arginine and cysteine composition at
10 (IL-10) and C-Reactive Protein (CRP) in
na Patient Group
CRP (mg/l)
CI Estimated Mean† 95% CI
–19.9 7.1 5.6–8.8
–39.2 6.3 2–13
–17.7 2 0.9–3.6
3, p 0.013). Evaluated at covariates in the model log HDL
, p  0.336), log triglyceride levels (F  5.91, p  0.018),
-10 was square root transformed before entering the model,
del: R2  0.368. ApoE genotype (F  9.36, p  0.001).
7.29, p 0.009) and b-blocker use (F 7.28, p 0.009).
odel, we present the squared estimated means.ukin-
ngi
95%
15.8
19.6
11.4
 4.6
0.94
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December 19, 2006:2471–81 ApoE Gene Locus and Serum IL-10 in CADesidues 112 and 158. Allele e2 has a cysteine at both 112 and
58 residues, whereas the e4 allele has arginine instead (24).
he e3 allele has cysteine at 112 and arginine at 158 and is the
ost common isoform observed in all populations (24).
It has been suggested that the presence of the e4 allele
ay lead to enhanced uptake of apoE containing lipopro-
eins and chylomicron remnants and, consequently, to a
igher concentration of cholesterol within the hepatocytes.
his may result in the down-regulation of the LDL
eceptor, which, in turn, might reduce LDL catabolism,
ccounting for the higher serum LDL concentrations ob-
erved in e4 carriers (24). Carriers of e2 alleles are less
fficient in the removal of very low-density lipoprotein and
hylomicron remnants because of the e2 allele’s lower
eceptor binding ability. Slower rates of hepatic clearance of
emnants might lead to lower hepatic cholesterol levels,
ore expression of LDL receptors, increase in LDL me-
abolism, and thus lower serum LDL cholesterol levels (24).
he present study showed significantly higher LDL cho-
esterol levels in E3/E4 carriers among CSA patients, and a
imilar, albeit not significant, trend among apoE genotypes
n ACS patients. In keeping with our results, other studies
n the literature have reported nonsignificant differences in
DL cholesterol levels among different apoE genotypes
5,14,25). Despite conflicting evidence there appears to be
ome modulation of the relation between apoE genotype
nd LDL cholesterol levels by amount and type of fat/
holesterol intake (23). Because the majority of our patients
ere on a Mediterranean diet characterized by low levels of
holesterol and high intake of unsaturated fat, it is possible
hat this type of diet could have attenuated the LDL-
odifying effect of apoE. However, in the ACS patient
roup (n  166) carriers of the e4 allele (n  35, LDL
holesterol: 144 mg/dl, IQR 112 to 166) had significantly
igher LDL cholesterol levels (p  0.046) compared with
on-e4 carriers (n131, LDL cholesterol: 126 mg/dl, IQR
16 to 143).
Furthermore, apoE regulates the inflammatory response.
polipoprotein E expression modifies both T-lymphocyte
nd macrophage cytokine production and thus appears to
irectly influence both the innate and the acquired immune
esponses (1). Our findings that E3/E4 carriers are associ-
ted with lower CRP levels are in agreement with previous
tudies suggesting an inverse relationship between CRP
evels and carriers of the e4 allele (13–15). This is a
urprising finding given the association of the apoE e4 allele
ith higher concentrations of LDL cholesterol (2,3) and
ncreased risk of CAD (4–6). Different and varying expla-
ations have been given for this awkward observation. März
t al. (15) suggested a “non-inflammatory” hypothesis,
ccording to which the CRP down-regulating effect of the
4 allele is not related to inflammation, suggesting that in e4
llele carriers the mevalonate pathway is down-regulated,
nd thus the CRP is low. Furthermore, in the same study
ärz et al. (15) proposed a “true anti-inflammatory” hy-
othesis in which the remnant lipoproteins accumulating in earriers of e2 acted as pro-inflammatory agents at the site of
he vessel wall and initiated or maintained a low-grade
ystemic inflammation, whereas their fast removal in e4
arriers led to an anti-inflammatory effect. Judson et al. (14)
nd Bach-Ngohou et al. (26) suggested that these anti-
nflammatory–related protective effects may be outweighed
y the lipid-related deleterious effects of the e4 allele.
owever, the contribution of the apoE allele to risk of
AD via its effects on plasma cholesterol levels seems to be
inimal (23,25). The novel finding in our study that E3/E4
arriers are associated with a trend toward reduced levels of
he anti-inflammatory cytokine IL-10 is of particular im-
ortance. It has been hypothesized that e4 allele carriers
ay show an “inflammatory imbalance” between pro- and
nti-inflammatory mediators rather than a true “anti-
nflammatory” profile. Previous studies (27) have shown, in
greement with our results, that e4 carriers are associated
ith attenuated anti-inflammatory activity. Human apoE
as antioxidant activity (1). Miyata and Smith (27) quanti-
ed apoE allele-specific antioxidant activity by means of
easuring allele-specific protection of cultured cells from
xidative cell death (27). In this regard, the e2 allele was
ound to be most effective in protecting from oxidative
amage, whereas the e4 allele was least effective.
Although the isoform-specific effects of apoE4 on IL-10
evels could be related to reduced antioxidant activity of
poE4 relative to apoE3, the mechanisms by which apoE
xerts its immunomodulatory effects remain incompletely
nderstood. A possibility exists, as suggested by recent
eurology studies (28,29), that cellular Ca homeostasis
ay be affected by apoE4, which in an isoform-specific
ashion could stimulate the influx of extracellular Ca into
euronal cells. Furthermore, it has been shown (30) that
poE is capable of initiating a calcium-dependent signaling
esponse in immunocompetent cells, also in an isoform-
pecific manner. Accordingly it is conceivable that apoE
ould attenuate basal IL-10 production by immune cells
i.e., T lymphocytes, macrophages, and monocytes) through
n increased influx of Ca and a consequent disregulation
f Ca homeostasis. However, the possibility that the
ffects of the e4 allele on serum IL-10 levels are mediated by
ther mechanisms cannot be excluded.
Interleukin-10 is capable of down-regulating numerous
nflammatory pathways that play an important role in the
rogression and stability of atherosclerotic plaque, including
nhibition of the pro-inflammatory transcription factor nu-
lear factor kappa B leading to suppressed cytokine produc-
ion (31). Furthermore, IL-10 inhibits matrix metallopro-
einase production (32), tissue factor (33), and adhesion
olecule expression (34), as well as the release of potent
hemoattractants (35).
Recent in vitro and animal studies have demonstrated
hat IL-10 expression in advanced human atherosclerotic
laques is associated with anti-atherogenic effects and ath-
romatous plaque stability (36). Clinical studies showed that
levated IL-10 serum levels are associated with a better
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CS, compared with patients with lower IL-10 levels (12).
f importance, Heeschen et al. (12) reported that the
eneficial effects of elevated serum IL-10 were present also
n patients with elevated serum CRP levels. Therefore, we
peculate that in e4 carriers, the deleterious effects of low
L-10 levels may outweigh the protective effects of low CRP
evels found in these patients, and that an imbalance
etween anti- and pro-inflammatory forces may be respon-
ible for the increased CAD risk associated with the e4
poE genotype. Theoretically, low IL-10 levels along with
ow CRP levels in e4 carriers could simply reflect the
resence of a counter-regulatory response to inflammatory
timuli. However, this is unlikely to be the case in the
resent study, as no association was found between serum
L-10 levels and CRP levels either in the ACS or CSA
atients, nor among the 3 different apoE genotypes.
Despite the novelty and importance of our findings, our
tudy may have limitations. First, we have not provided data
egarding clinical outcome in our patients, which would
ave further strengthened our hypothesis that low IL-10
oncentrations could have accounted for the increased
ardiovascular risk encountered in e4 carriers in the presence
f low CRP levels. However, the design of the present study
id not allow us to specifically investigate this issue. Larger,
d hoc prospective studies are required to establish the
rognostic value of our findings.
Second, in agreement with previous studies, CSA pa-
ients in our study had higher IL-10 levels (21) and lower
RP levels (37), but we did not see differences in e4 allele
requency between CAD patients with clinical stable disease
ersus those with unstable disease. The lack of an associa-
ion between differences in e4 frequency and IL-10 levels
mong CSA and ACS patients is likely to be due to the
elatively small patient sample, as these associations largely
epend on the prevalence of the e4 allele in the study
opulation. However, the finding in the present study that
he e4 allele is associated with a trend toward lower IL-10
evels in CSA patients, independent of the possible con-
ounding effects of acute clinical events or the presence of
yocardial necrosis, further strengthens the hypothesis of
n association between apoE genetic polymorphism and
irculating IL-10 levels. We may also have included CAD
atients with a higher prevalence of cardiovascular risk
actors. However, even if such a bias existed, it is unlikely
hat it would have substantially influenced our results, as we
ccounted for factors potentially affecting CRP and IL-10
oncentrations using multivariable models. Moreover, apoE
enotype frequencies found in our study are similar to those
eported previously in other CAD series (14,15,23,25).
Another limitation of the study is that post-hoc analysis
ddressing the type I error risk associated with multiple a
riori pairwise comparisons showed marginally significant
ifferences in certain pairwise comparisons regarding IL-10
evels. The inability of the present study to show significant
ifferences in all pairwise comparisons probably reflects themall study sample size. However, even with this relatively
mall patient number, our study showed that apoE gene
ocus polymorphism significantly correlates with circulating
L-10 levels. Moreover, our study also showed a trend
oward lower IL-10 levels among e4 carriers. Larger studies
re needed to validate our preliminary results in geograph-
cally diverse study populations and among the whole
pectrum of apoE gene polymorphisms. Finally, reporting
esults with more than 1 inflammatory marker could have
rovided more information regarding the immunomodula-
ory effects of apoE4. However, we assessed only CRP, as it
s the only inflammatory marker that has been suggested to
ave a role for risk stratification in cardiovascular disease
38,39).
In conclusion, our study demonstrated that a common
olymorphism of apoE is associated with lower circulating
oncentrations of IL-10 in ACS and CSA patients. The
resent study provides the first indication for the existence
f such a relationship and may provide a possible explana-
ion for the previously reported findings of an increased
ardiovascular risk in e4 carriers despite low CRP levels.
ur findings are also likely to stimulate further research on
he impact of apoE polymorphism on the various inflam-
atory pathways related to CAD risk.
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